Renal Vasculitis in the Elderly

  • David Jayne


Idiopathic Pulmonary Fibrosis Giant Cell Arteritis Crescentic Glomerulonephritis Rapidly Progressive Glomerulonephritis Central Nervous System Vasculitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kohli, H.S., Bhat, A., Aravindan, et al. Spectrum of renal failure in elderly patients. Int. Urol. Nephrol. 2007; 23:23.Google Scholar
  2. 2.
    Hauer, H.A., Bajema, I.M., van Houwelingen, H.C., et al. Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int. 2002; 61:80–89.PubMedCrossRefGoogle Scholar
  3. 3.
    Ulm, S., Hummel, M., Emig, M., et al. Leukocytoclastic vasculitis and acute renal failure after influenza vaccination in an elderly patient with myelodysplastic syndrome. Onkologie 2006; 29:470–472. Epub 2006 Sep 27.Google Scholar
  4. 4.
    Jennette, J.C., Falk, R.J., Andrassy, K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37:187–192.PubMedCrossRefGoogle Scholar
  5. 5.
    Muller, E., Schneider, W., Kettritz, U., Schmidt, W.A., Luft, F.C., Gobel, U. Temporal arteritis with pauci-immune glomerulonephritis: A systemic disease. Clin. Nephrol. 2004; 62:384–386.PubMedGoogle Scholar
  6. 6.
    Jayne, D.R., Marshall, P.D., Jones, S.J., Lockwood, C.M. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990; 37:965–970.PubMedCrossRefGoogle Scholar
  7. 7.
    Eisenberger, U., Fakhouri, F., Vanhille, P., et al. ANCA-negative pauci-immune renal vasculitis: Histology and outcome. Nephrol. Dial. Transplant 2005; 20: 1392–1399. Epub 2005 Apr 26.PubMedCrossRefGoogle Scholar
  8. 8.
    Watts, R.A., Scott, D.G. Epidemiology of the vasculitides. Sem. Respir. Crit. Care Med. 2004; 25:455–464.CrossRefGoogle Scholar
  9. 9.
    Krafcik, S.S., Covin, R.B., Lynch, J.P., III, Sitrin, R.G. Wegener’s granulomatosis in the elderly. Chest 1996; 109:430–437.PubMedGoogle Scholar
  10. 10.
    Vassallo, M., Shepherd, R.J., Iqbal, P., Feehally, I. Age-related variations in presentation and outcome in Wegener’s granulomatosis. J. Roy. Coll. Phys. Lond. 1997; 31:396–400.Google Scholar
  11. 11.
    Rychlik, I., Jancova, E., Tesar, V., et al. The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994–2000. Nephrol. Dial. Transplant 2004; 19:3040–3049. Epub 2004 Oct 26.PubMedCrossRefGoogle Scholar
  12. 12.
    Hewins, P., Savage, C.O. ANCA and neutrophil biology. Kidney Blood Press. Res. 2003; 26:221–225.PubMedCrossRefGoogle Scholar
  13. 13.
    Xiao, H., Heeringa, P., Hu, P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 2002; 110:955–963.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang, Y., Zhao, M.H., Yu, J., et al. The clinical and pathological characteristics of Chinese elderly patients with anti-neutrophil cytoplasmic autoantibodies associated small vessel vasculitis. Exp. Gerontol. 2004; 39:1401–1405.PubMedCrossRefGoogle Scholar
  15. 15.
    Abdulahad, W.H., van der Geld, Y.M., Stegeman, C.A., Kallenberg, C.G. Persistent expansion of CD4+ effector memory T cells in Wegener’s granulomatosis. Kidney Int. 2006; 70:938–947. Epub 2006 Jul 12.PubMedCrossRefGoogle Scholar
  16. 16.
    Birck, R., Warnatz, K., Lorenz, H.M., et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol. 2003; 14:440–447.PubMedCrossRefGoogle Scholar
  17. 17.
    Frampton, G., Jayne, D.R., Perry, G.J., Lockwood, C.M., Cameron, J.S. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin. Exp. Immunol. 1990; 82:227–232.PubMedCrossRefGoogle Scholar
  18. 18.
    Booth, A.D., Almond, M.K., Burns, A., et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am. J. Kidney Dis. 2003; 41:776–784.PubMedGoogle Scholar
  19. 19.
    Harper, L., Savage, C.O. ANCA-associated renal vasculitis at the end of the twentieth century—A disease of older patients. Rheumatology (Oxford) 2005; 44:495–501. Epub 2004 Dec 21.CrossRefGoogle Scholar
  20. 20.
    Hauer, H.A., Bajema, I.M., Van Houwelingen, H.C., et al. Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002; 62:1732–1742.PubMedCrossRefGoogle Scholar
  21. 21.
    Merkel, P.A., Seo, P., Aries, P., et al. Current status of outcome measures in vasculitis: Focus on Wegener’s granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J. Rheumatol. 2005; 32:2488–2495.PubMedGoogle Scholar
  22. 22.
    De Groot, K., Rasmussen, N., Bacon, P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52:2461–2469.PubMedCrossRefGoogle Scholar
  23. 23.
    Jayne, D., Rasmussen, N., Andrassy, K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003; 349:36–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Le Thi Huong, D., Wechsler, B., Piette, J.C., et al. [Wegener’s granulomatosis in elderly subjects. 37 cases.] [in French] Presse Med. 1988; 17:2379–2382.PubMedGoogle Scholar
  25. 25.
    Nada, A.K., Torres, V.E., Ryu, J.H., Lie, J.T., Holley, K.E. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin. Proc. 1990; 65:847–856.PubMedGoogle Scholar
  26. 26.
    Jayne, D.R., Rasmussen, N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin. Proc. 1997; 72:737–747.PubMedCrossRefGoogle Scholar
  27. 27.
    de Groot, K., Adu, D., Savage, C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol. Dial. Transplant 2001; 16:2018–2027.PubMedCrossRefGoogle Scholar
  28. 28.
    Hoffman, G.S., Kerr, G.S., Leavitt, R.Y., et al. Wegener granulomatosis: An analysis of 158 patients. Ann. Intern. Med. 1992; 116:488–498.PubMedGoogle Scholar
  29. 29.
    Haubitz, M., Bohnenstengel, F., Brunkhorst, R., Schwab, M., Hofmann, U., Busse, D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002; 61:1495–1501.PubMedCrossRefGoogle Scholar
  30. 30.
    Pusey, C.D., Rees, A.J., Evans, D.J., Peters, D.K., Lockwood, C.M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991; 40:757–763.PubMedCrossRefGoogle Scholar
  31. 31.
    Boomsma, M.M., Stegeman, C.A., van der Leij, M.J., et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum. 2000; 43:2025–2033.PubMedCrossRefGoogle Scholar
  32. 32.
    Sanders, J.S., Huitma, M.G., Kallenberg, C.G., Stegeman, C.A. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006; 45:724–729. Epub 2006 Jan 6.CrossRefGoogle Scholar
  33. 33.
    Jayne, D.R., Chapel, H., Adu, D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Quar. J. Med. 2000; 93:433–439.Google Scholar
  34. 34.
    Ito-Ihara, T., Ono, T., Nogaki, F., et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin. Pract. 2006; 102:c35–42. Epub 2005 Sep 19.PubMedCrossRefGoogle Scholar
  35. 35.
    Etanercept plus standard therapy for Wegener’s granulomatosis. N. Engl. J. Med. 2005; 352:351–361.Google Scholar
  36. 36.
    Booth, A., Harper, L., Hammad, T., et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 2004; 15:717–721.PubMedCrossRefGoogle Scholar
  37. 37.
    Smith, K.G., Jones, R.B., Burns, S.M., Jayne, D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 2006; 54:2970–2982.PubMedCrossRefGoogle Scholar
  38. 38.
    de Lind van Wijngaarden, R.A., Hauer, H.A., Wolterbeek, R., et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J. Am. Soc. Nephrol. 2006; 17:2264–2274. Epub 2006 Jul 6.Google Scholar
  39. 39.
    Rutgers, A., Slot, M., van Paassen, P., van Breda Vriesman, P., Heeringa, P., Tervaert, J.W. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am. J. Kidney Dis. 2005; 46:253–262.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • David Jayne

There are no affiliations available

Personalised recommendations